Phase III Study to Evaluate the Efficacy and Safety of AD-209
NCT06348576
·
clinicaltrials.gov ↗
PHASE3
Phase
RECRUITING
Status
280
Enrollment
INDUSTRY
Sponsor class
Conditions
Hypertension,Essential
Interventions
DRUG:
AD-209
DRUG:
AD-2091
DRUG:
AD-209 Placebo
DRUG:
AD-2091 Placebo
Sponsor
Addpharma Inc.